Rehovot, Israel – April 08, 2014 – Evogene Ltd. (NYSE, TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, today announced that it has filed its annual report containing audited consolidated financial statements for the year ended December 31, 2013 with the United States Securities and Exchange Commission, on Form 20-F. The annual report is available on the Evogene website (www.evogene.com).
Shareholders may receive a printed copy of the annual report free of charge upon request to the Company by using the contact details provided at the end of this press release.
About Evogene Ltd.
Evogene (NYSE, TASE: EVGN) is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a
complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on a deep scientific understanding of plant genomics and proprietary computational capabilities. The company has strategic collaborations with world-leading agricultural companies to develop improved seed
traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has early stage operations in agriculture chemicals and seeds for second generation
feedstock for biodiesel. For more information, please visit www.evogene.com
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene’scontrol, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forwardlooking statements to reflect future events or developments or changes in expectations, estimates,
projections and assumptions.
Contact:
Karen Mazor
Director, Public and Investor Relations
T: +972 54 22 88 039
karen.mazor@evogene.com